Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 19.11.2007 Extraordinary general meeting to confirm statutory restrictions on share registration D i e t l i k o n, 19 November 2007 - The Board of Directors of ...
NHMRC Clinical Trials Centre - The University of Sydney
Sydney, November 6 (ots/PRNewswire) - - First Lipid Modifying Agent Shown to Reduce Risk of Leading Causes of Blindness and Deteriorating Vision in Patients With Type 2 Diabetes - Reduces Need for Laser Treatment in Patients With and Without Known Diabetic Retinopathy - Significantly Decreases Progression of Diabetic Eye Disease Fenofibrate is the ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies/Disclosure of shareholdings Bern (euro adhoc) - On November 01, 2007, a group consisting of the following members: a) GoldenPeaks Capital Management Ltd., 4th Floor Cardinal Plaze, PO BOX ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 02.11.2007 D i e t l i k o n, 2 November 2007 - The Board of Directors of Implenia AG is aware of the preliminary notification published this morning of a public offer to acquire the entire share capital of Implenia AG. Its ...
Paris (ots/PRNewswire) - - Novel Compound Offers Hope to Patients not Adequately Responding to Laxative Treatment Data presented for the first time today at the international gastroenterology meeting UEGW (United European Gastroenterology Week) confirm the effectiveness and safety of RESOLOR(R) ...
Montreal, Canada (ots/PRNewswire) - - Approximately US$2 Million in Contracts Awarded Recently TORR Canada Inc. (TSX: TOR) ("TCI"), dedicated to providing innovative process solutions to the Oil & Gas industry, today provides an update following its acquisition of Pure Group AS. During the last few weeks, two of the recently acquired business units ...
Basel, Switzerland (ots/PRNewswire) - A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly less pain immediately after injection than SC darbepoetin-alfa (Aranesp).(1) These findings are important because to date there has been minimal data regarding SC injection ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information/Übernahme 29.10.2007 Adhoc - R E L E A S E PALFINGER takes over one of the global leaders in tail lift manufacturing o 100 percent acquisition of MBB Liftsystems AG o Considerable strengthening of the TAIL LIFT product ...
Montreal, Canada (ots/PRNewswire) - TORR Canada Inc. (TSX: TOR) ("TCI"), dedicated to providing innovative process solutions to the Oil & Gas industry, today announced the closing of the acquisition of all the shares of Norwegian-based Pure Group AS, a provider of leading technologies for oil, gas and water purification. This acquisition announced on July 30, 2007 will enable TCI to offer a broader product offering ...
Basel, Switzerland (ots/PRNewswire) - - MAXIMA Findings in the Lancet Affirm Ability to Maintain Haemoglobin Levels With Less Frequent Dosing A pivotal study published today in the Lancet has shown that dialysis patients can be effectively switched from frequently dosed anaemia drugs to an innovative new ...
Cranfield, England (ots/PRNewswire) - How far can the average customer drive a Nissan QASHQAI on one tank of fuel? The entire length of the UK and more if they drive economically. Seven test drivers from the Nissan Technical Centre Europe (NTCE) in Cranfield, Bedfordshire, proved this recently when they took turns piloting a 1.5dCi QASHQAI from Land's End on the southwest coast of England to John O'Groats on the ...
Montreal, Canada (ots/PRNewswire) - TORR Canada Inc. (TSX: TOR) ("TCI"), dedicated to providing water treatment to the Oil & Gas industry, today announced that its shareholders overwhelmingly approved the acquisition of all the shares of Norwegian-based Pure Group AS, a provider of leading technologies for oil, gas and water purification. This acquisition announced on July 30, 2007 will enable TCI to offer a broader ...
Toronto, Canada (ots/PRNewswire) - Many of the world's largest economies have a common malady handicapping their abilities to generate jobs and government revenues, according to an e- brief released today by the Institute. From the United States, Germany and Japan, to other engines of the global economy, they tend to have high corporate income tax rates that blunt ...
Callisto Pharmaceuticals. Inc.
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, announced today that complete enrollment of its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer) ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 6-month report 13.09.2007 D i e t l i k o n, 13 September 2007 - The Implenia Group, created with the merger of the two most important Swiss construction companies, Zschokke and Batigroup, ...
Auburn Hills, Michigan (ots/PRNewswire) - - Chairman and CEO Robert L. Nardelli teams former Toyota chief with Vice Chairman and President Thomas W. LaSorda - "World-class supply and demand leaders" - Joins Nardelli and LaSorda in new Office of the Chairman and on Board of Directors of Chrysler LLC - Press to run North American Sales, International Sales, Global Marketing, Product ...
Vienna, Austria (ots/PRNewswire) - - New analyses presented in Europe for the first time underscores REACH implications for individuals with leg artery blockages - Findings suggest the need for earlier, more aggressive therapeutic intervention New analyses from the REACH Registry presented at the ...
Consolidated Interim Financial Report as of June 30, 2007 Tip announcement for financial statements transmitted by euro adhoc. The issuer is responsible for the content of this announcement. The financial statement is available: in the internet at: ...
Callisto Pharmaceuticals. Inc.
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, today announced that the staff of the American Stock Exchange ("AMEX") has reviewed the Company's plan of compliance ...
Vancouver, Canada (ots/PRNewswire) - - Including 10m Grading 625 g/t Silver and 28m Grading 105 g/t Silver Tinka Resources Limited (the "Company") (TSXv - TK; Frankfurt - TLD; Pinksheets - TKRFF). Mr. Andrew Carter, President & CEO, provides the results of the first four drill holes of an eleven hole diamond drill exploration program currently underway at the Company's 100% owned Colquipucro silver project, ...
Zurich (ots) - As of October 1, 2007, Clariden Leu is simplifying its management structure and pooling its expertise in the investment products and services area in a newly-created division, Investment Products & Wealth Management Services. Hans ...
Maidenhead, England (ots/PRNewswire) - - Enhancements Provide Haemophilia B Patients with a Simpler and More Convenient Preparation Process for Recombinant Factor IX - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has received approval from the European Medicines Agency (EMEA) for new enhancements for BeneFix(R) nonacog ...
Rolle, Switzerland (ots/PRNewswire) - - EX Revealed 16 August at the 2007 Pebble Beach Concours d'Elegance - Innovative Coupe Crossover Concept - Standard 'ATTESA E-TS' All-Wheel Drive - Powered by a 3.5-litre 290hp V6 (US Specification) - First Introduction of the Advanced Around View Monitor System - To be Launched Progressively Across Europe Starting From Autumn 2008 Together With the G ...
Callisto Pharmaceuticals. Inc.
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine ...
Montreal, Canada (ots/PRNewswire) - TORR Canada Inc. (TSX: TOR) ("TORR"), dedicated to providing water treatment to the Oil & Gas industry, announces today that it has entered into an agreement with Hitec Vision Private Equity III AS and Statoil Innovation AS to acquire all the shares of Norwegian-based Pure Group AS, a provider of leading technologies for oil, gas and water purification. The purchase price of ...
Boehringer Ingelheim and Pfizer
Ingelheim, Germany (ots/PRNewswire) - - Patients to Benefit From Easy-to-Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market SPIRIVA(R) Respimat(R) in the European Union for people with chronic obstructive pulmonary disease (COPD). This positive ...
Chicago (ots/PRNewswire) - -- BYETTA offers added benefits of progressive weight loss in an analysis of the longest extension study to date -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced three-year, open-label study results that showed treatment with ...
Chicago (ots/PRNewswire) - - Study also showed added benefits of reductions in cardiovascular risk factors and progressive weight loss - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study that showed BYETTA(R) (exenatide) injection in ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 21.06.2007 Boudry, 21 June 2007 - The Neuchâtel-based industrial group Cicor Technologies, which specializes in complex printed circuit boards, in the complementary area of contract electronic manufacturing services and in ...
Oss, The Netherlands (ots/PRNewswire) - Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as compared to neostigmine, without ...